Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.272 USD | +1.00% | -15.52% | -66.26% |
Financials (USD)
Sales 2024 * | 25.22M | Sales 2025 * | 32.65M | Capitalization | 3.37M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -9M | EV / Sales 2024 * | 0.13 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.1 x |
P/E ratio 2024 * |
-0.15
x | P/E ratio 2025 * |
-0.63
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
Latest transcript on Eiger BioPharmaceuticals, Inc.
1 day | +1.00% | ||
1 week | -15.52% | ||
Current month | +5.70% | ||
1 month | +31.74% | ||
3 months | -60.55% | ||
6 months | -74.49% | ||
Current year | -66.26% |
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 0 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 2.272 | +1.00% | 1,301 |
24-05-09 | 2.25 | -13.46% | 11,869 |
24-05-08 | 2.6 | +7.00% | 5,743 |
24-05-07 | 2.43 | -6.54% | 274 |
24-05-06 | 2.6 | -3.35% | 4,526 |
Delayed Quote OTC Markets, May 10, 2024 at 02:43 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.26% | 3.37M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- EIGR Stock